logo-loader
viewFSD Pharma

FSD Pharma adds two leading cannabis researchers to Scientific Advisory Board

The Toronto-based company appointed Dr Ziva Cooper and Dr Mallory Loflin to its board, adding a wealth of experience in cannabinoid research and treatment efforts

research
Dr Cooper and Dr Loflin have extensive experience in cannabis and CBD research

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) added two leading cannabis researchers to the marijuana company’s Scientific Advisory Board, it announced Thursday.

The Toronto-based company brought on Dr Ziva Cooper and Dr Mallory Loflin following the recent appointment of two members to work with Dr Charles Pollack, the board’s chairman.

"It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board,” said Dr Raza Bokhari, executive co-chairman and CEO at FSD.

READ: FSD Pharma welcomes world-renowned cannabis trio to scientific advisory board

Bokhari said the board, which also includes Dr. Daniel Piomelli and Dr. Ryan Vandrey, is “shaping into a very robust body of scientists and researchers under the leadership of my good friend Dr. Pollack.”

Ziva Cooper, PhD, is the research director at UCLA’s Cannabis Research Initiative and has been involved with studies investigating cannabis neurobiology and dependence for over 10 years. Her current research is directed towards understanding the neurobiological, pharmacological and behavioural variables that influence the therapeutic potential and side effects of cannabis and CBD.

Mallory Loflin, PhD, is a research scientist at Veterans Affairs San Diego Healthcare System and an assistant professor of psychiatry at the University of California San Diego School of Medicine. Her research focuses on prevention efforts for problematic use of cannabinoids, and the development of CBD-based therapeutics.

“We are counting on the invaluable input of our SAB members as we continue to explore the value add of potential applications of medicinal grade cannabis and synthetic cannabinoid pharmaceuticals," said Bokhari in a statement.

FSD Pharma develops indoor grown, pharmaceutical grade cannabis and is also focused on research and development of novel cannabinoid-based treatments for several central nervous system disorders.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: FSD Pharma

Price: 5.45 CAD

CSE:HUGE
Market: CSE
Market Cap: $42.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FSD Pharma 'hunkering down' on grow facility and 'doubling...

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) CEO Raza Bokhari reveals 3Q highlights for the medically-focused cannabis company. Bokhari says the Canadian company is 'hunkering down' on its cannabis grow facility and 'doubling down' on its biosciences effort, advancing its Phase 1 safety trials...

1 week, 1 day ago

2 min read